John M. Evans sold $1.4M of BEAM
CEO at Beam Therapeutics Inc.. 50,000 shares at an average of $28.87, traded Jan 29, 2026, filed Feb 2, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.4M at market
- 0Share of holdings soldSold 4.9% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-033600, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 29, 2026 | MOption exercise Common Stock10b5-1 | +19,336 | $0.67 | $13k | 1,006,003 | Feb 2, 2026 |
| Jan 29, 2026 | MOption exercise Common Stock10b5-1 | +5,664 | $0.67 | $3,795 | 1,011,667 | Feb 2, 2026 |
| Jan 29, 2026 | SOpen-market sale Common Stock10b5-1 | -16,333 | $29.19 | $477k | 995,334 | Feb 2, 2026 |
| Jan 29, 2026 | SOpen-market sale Common Stock10b5-1 | -8,667 | $29.74 | $258k | 986,667 | Feb 2, 2026 |
| Jan 30, 2026 | MOption exercise Common Stock10b5-1 | +25,000 | $0.67 | $17k | 1,011,667 | Feb 2, 2026 |
| Jan 30, 2026 | SOpen-market sale Common Stock10b5-1 | -22,094 | $28.27 | $625k | 989,573 | Feb 2, 2026 |
| Jan 30, 2026 | SOpen-market sale Common Stock10b5-1 | -2,906 | $29.00 | $84k | 986,667 | Feb 2, 2026 |
| Jan 29, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -19,336 | $0.00 | $0 | 0 | Feb 2, 2026 |
| Jan 29, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,664 | $0.00 | $0 | 93,672 | Feb 2, 2026 |
| Jan 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 68,672 | Feb 2, 2026 |
| Jan 31, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +180,000 | $0.00 | $0 | 180,000 | Feb 2, 2026 |
Related signals
Other insiders at Beam Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $4,565 187 shares | -0% | |
| 15Weak | Beam Therapeutics Inc. | Giuseppe Ciaramella President | $1.1M 35,000 shares | -16% | |
| 16Weak | Beam Therapeutics Inc. | Christine Bellon Chief Legal Officer | $47k 1,371 shares | -1% | |
| 34Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $217k 6,198 shares | -15% | |
| 26Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $91k 3,034 shares | -7% | |
| 35Weak | Beam Therapeutics Inc. | Christine Bellon Chief Legal Officer | $645k 18,629 shares | -16% | |
| 9Weak | Beam Therapeutics Inc. | Christine Bellon Chief Legal Officer | $34k 1,254 shares | -1% | |
| 21Weak | Beam Therapeutics Inc. | Sravan Kumar Emany Chief Financial Officer | $171k 6,294 shares | -8% | |
| 32Weak | BEAMsell Beam Therapeutics Inc. | Fmr LLC owner, other | $12k 459 shares | -97% | |
| 30Weak | Beam Therapeutics Inc. | John M. Evans CEO | $1.2M 50,000 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.